Prothena Reports Full Year 2025 Results, Details Restructuring Impact, and Projects Significantly Reduced 2026 Cash Burn

summarizeSummary

Prothena reported a $244.1 million net loss for 2025, driven by a Phase 3 program discontinuation and a 63% workforce reduction, but projects a significantly reduced cash burn of $50-$55 million for 2026, while advancing multiple partnered clinical programs.

check_boxKey Events

• Full Year 2025 Financial Results

  Reported a net loss of $244.1 million for the year ended December 31, 2025, with total revenue of $9.7 million. The accumulated deficit reached $1.3 billion.

• Significant Restructuring and Program Discontinuation

  Discontinued the Birtamimab development program in May 2025 due to Phase 3 trial results and implemented an approximate 63% workforce reduction in June 2025, with further reductions of 17 employees expected in 2026.

• Projected Reduced Cash Burn for 2026

  Forecasts net cash used in operating and investing activities to be approximately $50 million to $55 million for 2026, a significant reduction from the $163.6 million used in operating activities in 2025.

• Advancement of Partnered Clinical Pipeline

  Partners initiated Phase 3 trials for Prasinezumab (Parkinson's disease) and Coramitug (ATTR amyloidosis), and a Phase 2 trial for BMS-986446 (Alzheimer's disease). A new Phase 1 trial for PRX019 (neurodegenerative diseases) was also initiated with BMS, including an $80 million option exercise fee and potential milestones up to $617.5 million.

auto_awesomeAnalysis

This annual report provides a comprehensive financial and operational update for Prothena, highlighting a year of significant strategic shifts. While the company reported a substantial net loss and accumulated deficit for 2025, driven by the discontinuation of the Birtamimab program and a major workforce reduction, it also projects a significantly lower cash burn for 2026. This improved cash runway, coupled with ongoing advancements in its partnered pipeline programs (two in Phase 3, one in Phase 2, and a new Phase 1), indicates the company is actively managing its resources and progressing its core assets despite past setbacks. The full valuation allowance on deferred tax assets reflects a cautious outlook on future profitability. Investors should monitor the progress of the clinical trials and the company's ability to secure additional capital on favorable terms.